Abstract: Part One: Genetics and Immunology. Familial ovarian cancer. Hereditary ovarian cancer. Cytogenetic changes in human epithelial ovarian cancer. Molecular genetics of ovarian cancer. Molecular pathogenesis of ovarian cancer. Molecular structure and clinical applications of a cancer-associated mucin. Part Two: Oncogenes, growth factors and cytokines. Expression of the epidermal growth factor receptor, HER-2 neu and p53 in ovarian cancer. Factors regulating the growth of normal and malignant ovarian epithelium. Inhibition of breast and ovarian tumour cell growth by antibodies and immunotoxins reactive with distinct epitopes on the extracellular domain of HER-2 neu (c-erbB2). Cloning of genes encoding ovarian carcinoma-specific antigens. Cytokines and ovarian cancer. Characterization of cytokines produced by ovarian cancer cells. Role of interleukin-6 in ovarian cancer. CSF-1 and its receptor in ovarian and other gynaecological neoplasms. Regulation of growth of human ovarian cancer cells. Part Three: Drug resistance and experimental therapeutics. Signal transduction pathway regulation of cisplatin sensitivity. Immunotoxin therapy in ovarian cancer. Effects of granulocyte macrophage colony stimulating factor in cyclophosphamide- and carboplatin-treated patients. Mitochondrial poisons and ovarian cancer. TNFalpha mediated lysis in gynaecological malignancies. Chemo-immunotherapy with a combination of low-dose cisplatin and recombinant interleukin 2. Part Four: Pathology, early detection and prognosis. Early ovarian cancer. New techniques in the pathological assessment of ovarian cancer. Flow cytometry in ovarian cancer. Ultrasound for early cancer screening. Role of colour Doppler in an ultrasound-based screening programme. Transvaginal colour Doppler in the differentiation between benign and malignant ovarian masses. Role of CA-125 in screening for ovarian cancer. Advantages and disadvantages of randomized controlled trials of ovarian cancer screening. Part Five: Management. Intraperitoneal therapy in the management of ovarian cancer. Intraperitoneal cisplatin and interferon- alpha in persistent epithelial ovarian cancer: summary of phase I-II trials. Overview of randomized chemotherapy trials for advanced ovarian cancer. Meta-analysis of treatment for advanced ovarian cancer. Impact of maximal cytoreductive surgery on survival in advanced ovarian cancer. Management and outcome of stage III epithelial ovarian cancer. The role of surgery in epithelial ovarian cancer. Debulking surgery at second-look laparotomy. Evaluation of debulking surgery at second-look laparotomy. Second-look laparotomy in the routine management of ovarian cancer.
Publication Year: 1992
Publication Date: 1992-01-01
Language: en
Type: book
Access and Citation
Cited By Count: 11
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot